Cosmecca Korea Reports Q2 Revenue of 226.1 Billion Won, Jumps 40% on K-Derma Skincare Demand

Operating Profit Reaches 32.1 Billion Won, Net Profit 20.3 Billion Won
Skincare Sales Surge 94.8% at Korean Subsidiary
Growth Driven by Rising K-Derma Skincare Exports

Cosmecca Korea, a global OGM (Original Global Manufacturing) specialist in cosmetics, saw significant increases in revenue, operating profit, and net profit in the second quarter of this year. This performance is believed to result from the rising demand for K-Derma skincare products.

On August 10, Cosmecca Korea announced that, on a consolidated basis for the second quarter of 2026, revenue came in at 226.1 billion won and operating profit at 32.1 billion won. These figures represent increases of 39.8% and 39.3% year-on-year, respectively. Net profit also soared to 20.3 billion won, marking an 88.0% increase over the same period last year.

The company’s earnings growth was largely driven by the expansion of new clients, as well as reorders and SKU (stock-keeping unit) increases from existing clients. This so-called “snowball effect” means that initial purchase orders lead to repeated orders and a wider range of products. In particular, the global demand for K-Derma skincare products increased, resulting in a boost in export volumes.

The Korean subsidiary led overall performance, recording second-quarter revenue of 178.8 billion won and operating profit of 24.5 billion won. In particular, skincare sales surged 94.8% year-on-year. This was due to steady purchase orders for derma skincare products designed to meet needs based on specific skin concerns and efficacy.

Englewood Lab, the U.S. subsidiary, posted revenue of 51.9 billion won and operating profit of 8.7 billion won. By leveraging its OTC sun care production capacity in accordance with U.S. FDA standards, the company expanded partnerships with North American brands. It also increased orders through its "Ready To Go (RTG) OTC" solution, which supports everything from OTC product development to manufacturing for K-beauty clients. The operating profit margin for the U.S. subsidiary was 16.8%.

Cosmecca China, the China subsidiary, recorded revenue of 7.7 billion won and an operating loss of 1.2 billion won. Focusing on C-beauty and online clients, sales increased 21.3% compared to the previous quarter. In the second half of the year, the company plans to improve profitability by strengthening sales of sun care products, following on from cushion and primer categories.

Cosmecca Korea aims to continue responding to demand for derma skincare in the second half of the year, supported by its skin science-based formulation technologies, while also expanding personalized product proposals and developing new pipelines.

A representative from Cosmecca Korea stated, "As global demand for K-derma skincare continues to grow, client interest in our R&D capabilities and formulation technologies is increasing." The representative added, "We will further strengthen our global competitiveness through technological innovation and category expansion."

This content was produced with the assistance of AI translation services.